Strategic Actions
Beta Drugs has achieved regulatory approvals in Azerbaijan for its complete oncology portfolio across multiple dosage forms, including:
- Liquid injectables
- Lyophilised injectables
- Tablets and capsules
- Oral suspensions
Portfolio Expansion
The Company has already filed 15 oncology product dossiers for registration in Azerbaijan. An additional 15 oncology products are expected to be ready for filing within the next month, which will significantly expand the Company's oncology portfolio in the market.
Market Positioning
With this comprehensive portfolio, Beta Drugs expects to be one of the few oncology players present in the Azerbaijan market. This provides an opportunity to establish a meaningful presence across multiple oncology therapies and dosage forms.
Commercialisation Timeline
The Company is actively working towards commercialisation and aims to secure initial oncology business from Azerbaijan during the current financial year.
Strategic Context
The Azerbaijan expansion represents an important step in Beta Drugs' strategy to build its international oncology franchise and expand its presence across emerging global markets.